Top broker says CSL (ASX:CSL) share price is a buy

Is the CSL share price good value?

| More on:
Young doctor raising arms in air with hands in fists celebrating a new development

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The CSL Limited (ASX: CSL) share price has been underperforming the market again in 2021.

Since the start of the year, the biotherapeutics company's shares have risen 8.5%.

This compares to a 12.5% gain by the S&P/ASX 200 Index (ASX: XJO) over the same period.

Is the CSL share price good value?

One leading broker that believes the underperformance in the CSL share price is a buying opportunity is Morgans.

According to a recent note, the broker has put an add rating and $324.40 price target on its shares.

This compares to the latest CSL share price of $309.08.

What did Morgans say?

Morgans was pleased with CSL's performance in FY 2021, noting that its full year sales and profits were stronger than expected despite facing tough trading conditions. This resilient performance is partly why it remains positive on the CSL share price.

The broker was particularly impressed with CSL's Seqirus business, which smashed forecasts thanks to strong demand for influenza vaccines.

Commenting on the result, Morgans said: "FY21 results were solid, beating on both top (US$10,310m, +10% cc; Morgans US$9,816m) and bottom lines (US$2,375m, +10% cc; Morgans US$2,174m). Seqirus (15% of profit) was exceptional (US$1,736m, +30% in cc, EBIT US$483m, +95%, margin +7.4pp to 27.8%), underpinned by increased sales of seasonal influenza vaccines (+41%; record doses c130m) and ongoing shift to more differentiated products."

What about FY 2022?

Morgans acknowledges that FY 2022 will be a transitional year, with weaker margins, and an expected decline in profits.

It said: "FY22 guidance is targeting cc NPAT between US$2,150-2,250bn (-9% to -5%) on revenue growth between 2-5%, with management flagging a "transitional year", core plasma products "robust", but margins contracting on increased costs, and Seqirus strength ongoing."

However, it remains positive on the long term and believes CSL shares would be a great addition to a balanced portfolio.

It concluded: "We view CSL as a core holding and best positioned among its peers to meet growing patient demand, but the near term remains challenged, with timing uncertainty around a full recovery in plasma collections and increasing costs."

The CSL share price is up almost 200% over the last five years despite its recent underperformance.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and has recommended CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Broker Notes

a smiling woman sits at her computer at home with a coffee alongside her, as if pleased with her investments.
Broker Notes

Buy this undervalued ASX 200 stock for a 40%+ return

Goldman Sachs thinks this stock is heading a lot higher.

Read more »

a woman holds a facebook like thumbs up sign high above her head. She has a very happy smile on her face.
Broker Notes

Morgans says these 3 ASX 200 shares are buys

If you are looking for some new ASX 200 shares to buy, then read on! That's because the three named…

Read more »

A young woman lifts her red glasses with one hand as she takes a closer look at news about interest rates rising and one expert's surprising recommendation as to which ASX shares to buy
Broker Notes

5 ASX stocks for $5,000 investments in December

Let's find out which shares brokers are tipping as buys right now.

Read more »

A woman wearing a yellow shirt smiles as she checks her phone.
Broker Notes

Top brokers name 3 ASX shares to buy today

Here's what brokers are recommending as buys this week.

Read more »

three businessmen high five each other outside an office building with graphic images of graphs and metrics superimposed on the shot.
Broker Notes

3 ASX shares catching broker upgrades this week

Analysts are turning more constructive on these names.

Read more »

Modern accountant woman in a light business suit in modern green office with documents and laptop.
Technology Shares

Is the WiseTech share price heading for $200?

The path is set, according to one broker.

Read more »

A happy male investor turns around on his chair to look at a friend while a laptop runs on his desk showing share price movements
Broker Notes

Goldman Sachs says these ASX 300 stocks can rise 15% to 30%

Let's see what the broker is saying about these buy-rated stocks.

Read more »

A man has a surprised and relieved expression on his face. as he raises his hands up to his face in response to the high fluctuations in the Galileo share price today
Broker Notes

This ASX All Ords stock is undervalued and could rocket 60%+

Bell Potter is tipping this share to deliver big returns for investors.

Read more »